Gilead Sciences Inc. (GILD)

Gilead Sciences Inc. (GILD $141.29)
- $141.29 P/E (TTM): 21.33X Cap: $175.40B
- View GILD Profile
- View Questions on GILD

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Amgen Inc. (AMGN $351.48)
- $351.48 P/E (TTM): 25.38X Cap: $189.47B
- View AMGN Profile
- View Questions on AMGN
Gilead Sciences Inc. (GILD $141.29)
- $141.29 P/E (TTM): 21.33X Cap: $175.40B
- View GILD Profile
- View Questions on GILD
Intuitive Surgical Inc. (ISRG $477.73)
- $477.73 P/E (TTM): 61.34X Cap: $169.65B
- View ISRG Profile
- View Questions on ISRG
Regeneron Pharmaceuticals Inc. (REGN $744.12)
- $744.12 P/E (TTM): 18.3X Cap: $78.66B
- View REGN Profile
- View Questions on REGN
Eli Lilly and Company (LLY $918.05)
- $918.05 P/E (TTM): 40.54X Cap: $867.39B
- View LLY Profile
- View Questions on LLY
Merck & Company Inc. (MRK $114.50)
- $114.50 P/E (TTM): 15.92X Cap: $283.08B
- View MRK Profile
- View Questions on MRK

Q: I just sold a position in Regeneron, and I am looking to replace it with another name in the healthcare space. I already hold ISRG, but I am reticent to add to it while it seems to trade sideways. Lilly has performed well, but I am unsure if it is now fully valued.A recent interviewee on CNBC had mentioned Amgen and Gilead as names which could do well. Any suggestions for names to consider in the healthcare space? I’d be okay with both Canadian and US names. Thanks so much, and I look forward to your response.

Read Answer Asked by Domenic on February 18, 2026

Gilead Sciences Inc. (GILD $141.29)
- $141.29 P/E (TTM): 21.33X Cap: $175.40B
- View GILD Profile
- View Questions on GILD
Abbott Laboratories (ABT $108.49)
- $108.49 P/E (TTM): 29.76X Cap: $188.95B
- View ABT Profile
- View Questions on ABT
Merck & Company Inc. (MRK $114.50)
- $114.50 P/E (TTM): 15.92X Cap: $283.08B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $27.32)
- $27.32 P/E (TTM): 20.18X Cap: $155.40B
- View PFE Profile
- View Questions on PFE

Q: Would you recommend starting a new position now in these big pharma stocks with rotation out of the tech sector lately? All three have decent PE, PEG and PS ratios and have been fared well in last few bear markets overall. What would your recommended allocation be across the three stocks for an investment of time line of 5 years?
Thanks!

Read Answer Asked by Scott on December 17, 2025

Amgen Inc. (AMGN $351.48)
- $351.48 P/E (TTM): 25.38X Cap: $189.47B
- View AMGN Profile
- View Questions on AMGN
Gilead Sciences Inc. (GILD $141.29)
- $141.29 P/E (TTM): 21.33X Cap: $175.40B
- View GILD Profile
- View Questions on GILD
AbbVie Inc. (ABBV $208.34)
- $208.34 P/E (TTM): 93.12X Cap: $368.38B
- View ABBV Profile
- View Questions on ABBV
Abbott Laboratories (ABT $108.49)
- $108.49 P/E (TTM): 29.76X Cap: $188.95B
- View ABT Profile
- View Questions on ABT
The Cigna Group (CI $264.61)
- $264.61 P/E (TTM): 11.87X Cap: $69.73B
- View CI Profile
- View Questions on CI
Johnson & Johnson (JNJ $237.28)
- $237.28 P/E (TTM): 21.59X Cap: $571.51B
- View JNJ Profile
- View Questions on JNJ
Medtronic plc. (MDT $87.21)
- $87.21 P/E (TTM): 24.7X Cap: $111.96B
- View MDT Profile
- View Questions on MDT
Savaria Corporation (SIS $25.50)
- $25.50 P/E (TTM): 29.86X Cap: $5.81B
- View SIS Profile
- View Questions on SIS
- View Reports on SIS

Q: I am mostly content with my health care stocks with the exception of MDT. It has been essentially flat since about 2016 except for the dividend. It did peak around 2022 but has fallen down to previous levels.
What do you think of the longer term for MDT?
Would you make any other changes for slow but reliable growth and higher end of dividends.
As always, thank you for the great service.

Read Answer Asked by Tulio on August 21, 2025